Literature DB >> 33489855

Celecoxib induces apoptosis through Akt inhibition in 5-fluorouracil-resistant gastric cancer cells.

Seung Mi Choi1, Young Sik Cho1, Geumi Park1, Suk Kyeong Lee2, Kyung-Soo Chun1.   

Abstract

Gastric cancer is the fifth leading cause of cancer and a global public health problem. 5-Fluorouracil (5-FU) is the primary drug chosen for the treatment of advanced gastric cancer, but acquired cancer drug resistance limits its effectiveness and clinical use. Proliferation assays showed that a gastric carcinoma cell line, AGS and 5-FU-resistant AGS cells (AGS FR) treated with 3-100 μM 5-FU for 48 h or 72 h showed different sensitivities to 5-FU. Immunoblot assay demonstrated that AGS FR cells expressed more COX-2 and PGE2-cognated receptor EP2 than AGS cells. AGS FR cells considerably produced PGE2 than AGS upon stimulation with 5-FU. These results suggest that COX-2 expression is associated with 5-FU resistance. Unlike AGS FR cells, AGS cells showed increased levels of both cleaved caspase-3 and Bax following 5-FU treatment. Treatment of cells with the COX-2 selective inhibitor celecoxib induced cell death of AGS FR cells in a time- and concentration-dependent manner. FACS analysis showed that celecoxib at high doses caused apoptotic cell death, demonstrating a concentration-dependent increase in the cell populations undergoing early apoptosis and late apoptosis. This apoptotic induction was strongly supported by the expression profiles of apoptosis- and survival-associated proteins in response to celecoxib; pro-apoptotic cellular proteins increased while expressions of COX-2 and p-Akt were downregulated in a concentration-dependent manner. An increase in PTEN expression was accompanied with downregulation of p-Akt. Based on the data that downregulation of COX-2 was correlated with the concentrations of celecoxib, COX-2 may play a key role in celecoxib-induced cell death of AGS FR cells. Butaprost, the EP2 agonist, promoted proliferative activity of AGS FR cells in a concentration-dependent manner compared with AGS cells. In cells exposed to butaprost, expressions of COX-2 and p-Akt were increased in a concentration-dependent manner with concomitantly reduced PTEN levels. Taken together, 5-FU-resistance in gastric cancer is correlated with COX-2 expression, and therefore the selective inhibition of COX-2 leads to suppression of cell proliferation of AGS FR cells. Modulation of COX-2 expression and its catalytic activity may be a potential therapeutic strategy to overcome 5-FU-resistant gastric cancer. © Korean Society of Toxicology 2020.

Entities:  

Keywords:  5-FU; Akt; Chemoresistance; Cyclooxygenase-2; EP2; Gastric cancer

Year:  2020        PMID: 33489855      PMCID: PMC7806699          DOI: 10.1007/s43188-020-00044-3

Source DB:  PubMed          Journal:  Toxicol Res        ISSN: 1976-8257


  47 in total

1.  Activating PTEN by COX-2 inhibitors antagonizes radiation-induced AKT activation contributing to radiosensitization.

Authors:  Zhen Meng; Ye-Hua Gan
Journal:  Biochem Biophys Res Commun       Date:  2015-03-11       Impact factor: 3.575

2.  Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer.

Authors:  Eiji Oki; Hideo Baba; Eriko Tokunaga; Toshihiko Nakamura; Naoyuki Ueda; Motonori Futatsugi; Kohjiro Mashino; Manabu Yamamoto; Masahiko Ikebe; Yoshihiro Kakeji; Yoshihiko Maehara
Journal:  Int J Cancer       Date:  2005-11-10       Impact factor: 7.396

Review 3.  Chemopreventive effect of celecoxib in gastric cancer.

Authors:  S Futagami; K Suzuki; T Hiratsuka; T Shindo; T Hamamoto; N Ueki; M Kusunoki; K Miyake; K Gudis; T Tsukui; C Sakamoto
Journal:  Inflammopharmacology       Date:  2007-02       Impact factor: 4.473

4.  Increased expression of cyclooxygenase-2 protein in human gastric carcinoma.

Authors:  H Y Lim; H J Joo; J H Choi; J W Yi; M S Yang; D Y Cho; H S Kim; D K Nam; K B Lee; H C Kim
Journal:  Clin Cancer Res       Date:  2000-02       Impact factor: 12.531

5.  Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.

Authors:  Xiangguo Liu; Ping Yue; Zhongmei Zhou; Fadlo R Khuri; Shi-Yong Sun
Journal:  J Natl Cancer Inst       Date:  2004-12-01       Impact factor: 13.506

6.  Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin.

Authors:  Kyung-Soo Chun; Su-Hyeong Kim; Yong-Sang Song; Young-Joon Surh
Journal:  Carcinogenesis       Date:  2004-01-16       Impact factor: 4.944

Review 7.  The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment.

Authors:  Alexander Greenhough; Helena J M Smartt; Amy E Moore; Heather R Roberts; Ann C Williams; Christos Paraskeva; Abderrahmane Kaidi
Journal:  Carcinogenesis       Date:  2009-01-09       Impact factor: 4.944

8.  TGF-β1 stimulates cyclooxygenase-2 expression and PGE2 production of human dental pulp cells: Role of ALK5/Smad2 and MEK/ERK signal transduction pathways.

Authors:  Po-Shuen Lin; Ru-Hsiu Cheng; Mei-Chi Chang; Jang-Jaer Lee; Hsiao-Hua Chang; Wei-Ling Huang; Sin-Yuet Yeung; Ya-Ching Chang; Jiiang-Huei Jeng
Journal:  J Formos Med Assoc       Date:  2017-08-02       Impact factor: 3.282

9.  Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in Vitro and in Vivo.

Authors:  Zhi-Jun Dai; Xiao-Bin Ma; Hua-Feng Kang; Jie Gao; Wei-Li Min; Hai-Tao Guan; Yan Diao; Wang-Feng Lu; Xi-Jing Wang
Journal:  Cancer Cell Int       Date:  2012-12-19       Impact factor: 5.722

10.  Relationship between tumour PTEN/Akt/COX-2 expression, inflammatory response and survival in patients with colorectal cancer.

Authors:  Antonia K Roseweir; Arfon G M T Powell; Lindsay Bennett; Hester C Van Wyk; James Park; Donald C McMillan; Paul G Horgan; Joanne Edwards
Journal:  Oncotarget       Date:  2016-10-25
View more
  3 in total

Review 1.  The Role of Lipid Metabolism in Gastric Cancer.

Authors:  Meng-Ying Cui; Xing Yi; Dan-Xia Zhu; Jun Wu
Journal:  Front Oncol       Date:  2022-06-15       Impact factor: 5.738

Review 2.  Looking at NSAIDs from a historical perspective and their current status in drug repurposing for cancer treatment and prevention.

Authors:  Adem Ozleyen; Yakup Berkay Yilmaz; Serhat Donmez; Hazal Nazlıcan Atalay; Gizem Antika; Tugba Boyunegmez Tumer
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-25       Impact factor: 4.322

3.  High Levels of Hyaluronic Acid Synthase-2 Mediate NRF2-Driven Chemoresistance in Breast Cancer Cells.

Authors:  Bo-Hyun Choi; Ingeun Ryoo; Kyeong Hwa Sim; Hyeon-Jin Ahn; Youn Ju Lee; Mi-Kyoung Kwak
Journal:  Biomol Ther (Seoul)       Date:  2022-07-01       Impact factor: 4.231

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.